Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A
Science Translational Medicine · 2024
DOI: 10.1126/scitranslmed.adh0027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Amy W Strilchuk und 20 weiteren Autor:innen. Beteiligte Einrichtung: Michael Smith Laboratories, University of British Columbia, Vancouver V6T 1Z4, Canada. Hauptthemen laut MEDLINE: Antifibrinolytic Agents, Hemophilia A, Hemostatics, Liposomes. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Antifibrinolytic drugs are used extensively for on-demand treatment of severe acute bleeding. Controlling fibrinolysis may also be an effective strategy to prevent or lessen chronic recurring bleeding in bleeding disorders such as hemophilia A (HA), but current antifibrinolytics have unfavorable pharmacokinetic profiles. Here, we developed a long-lasting antifibrinolytic using small interfering RNA (siRNA) targeting plasminogen packaged in clinically used lipid nanoparticles (LNPs) and tested it to determine whether reducing plasmin activity in animal models of HA could decrease bleeding frequency and severity. Treatment with the siRNA-carrying LNPs reduced circulating plasminogen and suppressed fibrinolysis in wild-type and HA mice and dogs. In HA mice, hemostatic efficacy depended on the injury model; plasminogen knockdown improved hemostasis after a saphenous vein injury but not tail vein transection injury, suggesting that saphenous vein injury is a murine bleeding model sensitive to the contribution of fibrinolysis. In dogs with HA, LNPs carrying siRNA targeting plasminogen were as effective at stabilizing clots as tranexamic acid, a clinical antifibrinolytic, and in a pilot study of two dogs with HA, the incidence of spontaneous or excess bleeding was reduced during 4 months of prolonged knockdown. Collectively, these data demonstrate that long-acting antifibrinolytic therapy can be achieved and that it provides hemostatic benefit in animal models of HA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Michael Smith Laboratories, University of British Columbia, Vancouver V6T 1Z4, Canada.
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver V6T 2A1, Canada.
- Department of Pathology and Laboratory Medicine and UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
- National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
- Blood Research Institute, Versiti, Milwaukee, WI 53226, USA.
ORCID-Profile: Amy W Strilchuk, Woosuk S Hur, Sara R Abrahams, Jerry Leung, Lakmali M Silva, Jocelyn A Schroeder, Kate Nesbitt, Bas de Laat, Niki M Moutsopoulos, Thomas H Bugge, Qizhen Shi, Pieter R Cullis, Alisa S Wolberg, Matthew J Flick, David Lillicrap, Timothy C Nichols, Christian J Kastrup
Förderung
- NIDCR NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Strilchuk, A. W., Hur, W. S., Batty, P., Sang, Y., Abrahams, S. R., Yong, A. S. M., Leung, J., Silva, L. M., Schroeder, J. A., Nesbitt, K., de Laat, B., Moutsopoulos, N. M., Bugge, T. H., Shi, Q., Cullis, P. R., Merricks, E. P., Wolberg, A. S., Flick, M. J., Lillicrap, D., …, & Kastrup, C. J. (2024). Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adh0027
Vancouver
Strilchuk AW, Hur WS, Batty P, Sang Y, Abrahams SR, Yong ASM, et al. Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.adh0027
BibTeX
@article{Strilchuk2024,
author = {Strilchuk, Amy W and Hur, Woosuk S and Batty, Paul and Sang, Yaqiu and Abrahams, Sara R and Yong, Alyssa S M and Leung, Jerry and Silva, Lakmali M and Schroeder, Jocelyn A and Nesbitt, Kate and de Laat, Bas and Moutsopoulos, Niki M and Bugge, Thomas H and Shi, Qizhen and Cullis, Pieter R and Merricks, Elizabeth P and Wolberg, Alisa S and Flick, Matthew J and Lillicrap, David and Nichols, Timothy C and Kastrup, Christian J},
title = {Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A},
journal = {Science Translational Medicine},
year = {2024},
doi = {10.1126/scitranslmed.adh0027}
}
EUVIMED